New York Halts Dispensary Licenses Amid Lawsuit Over Cannabis Equity
Licenses for new cannabis dispensaries are temporarily suspended following a lawsuit filed by service-disabled veterans.
Licenses for new dispensaries in New York were halted on Monday, August 7th, 2023 due to a lawsuit filed last week against the state Cannabis Control Board and the state Office of Cannabis Management (OCM) (1). Dispensaries that were already issued licenses are being blocked from receiving operational approval (1). The lawsuit, filed by four service-disabled veterans, claimed the licensing program used by regulators does not align with the program set forth by the Marijuana Regulation and Taxation Act (MRTA) (2).
Under the program used by the OCM, priority for licensing is given to individuals with prior cannabis convictions as opposed to the social equity groups set forth in the MRTA (2). The four veterans would qualify under the state law, which also included minority-owned businesses, women-owned businesses along with communities historically affected by disproportionate cannabis enforcement (1).
“The Office of Cannabis Management is aware of the court’s order, and is adhering to its requirements,” said Trivette Knowles, an OCM spokesperson (3). “We are actively communicating with CAURD [Conditional Adult Use Retail Dispensary program] applicants and provisionally approved licensees to inform them of the impact of the Court’s order on OCM operations.”
The MRTA was signed into law in March 2021 and created a process for license and tax revenue distribution, expunged minor prior cannabis convictions, and also allowed home cultivation for recreational use (4). Medical cannabis was legalized in the state in 2014 (4).
Currently there are around 20 legal dispensaries operating in the state and hundreds operating illegally (1,3).
The judge issuing the stated in his order “that there is genuine urgency and that immediate and irreparable injury, loss, or damage will result” if the licensing program moves forward,” (1). A hearing for the case is planned for Friday, August 11th (1).
Two other lawsuits have been filed against the OCM, one late last year and one in April 2023 (2).
References
- Zhang, M. New York Cannabis Dispensary openings halted by court order https://www.politico.com/news/2023/08/07/ny-court-halts-cannabis-dispensary-openings-00110182 (accessed Aug 8, 2023).
- Lewis, C. No new dispensaries: Judge pauses rollout of NY’s legal cannabis industry https://gothamist.com/news/no-new-dispensaries-judge-pauses-rollout-of-new-york-legal-weed-cannabis-industry (accessed Aug 8, 2023).
- Christmann, S. Another lawsuit puts a hold on cannabis dispensary openings https://buffalonews.com/business/local/new-york-cannabis-dispensary-lawsuit/article_773297f2-35f1-11ee-a548-bb852b09be66.html (accessed Aug 8, 2023).
- Norml. New York: Governor signs adult-use legalization measure into law https://norml.org/news/2021/04/01/new-york-governor-signs-adult-use-legalization-measure-into-law/ (accessed Aug 8, 2023).
Ep 24, Part III: Data Transparency in Cannabis Testing with Yasha Kahn
December 26th 2024In the final part of this episode, Evan Friedmann and Yasha Kahn discuss the need for a national entity to centralize cannabis data collection, moving from snapshot data to continuous updates. They emphasize the importance of accurate lab data and adverse event tracking, suggesting QR codes on packaging to report issues. Yasha suggests harsher consequences for result manipulation and suggests collaboration between state departments and federal entities to support underfunded regulators. They also discuss the potential benefits of off-the-shelf testing and the importance of stability testing. Finally, Yasha shares his top three reading recommendations for the audience.
Ep 24, Part II: Data Transparency in Cannabis Testing with Yasha Kahn
December 12th 2024Evan Friedmann and Yasha Kahn, co-founder of MCR Labs, discuss the discrepancies between current regulations and data on mycotoxins and pesticides in cannabis products. They highlight the need for updated regulations based on new data, emphasizing the importance of accurate testing and labeling. They also discuss the issue of result manipulation, particularly in THC content, and the need for public health officials to address this. Yasha suggests making testing data public to enhance oversight and suggests a national entity to manage this data for better consistency and public safety.
